" class="no-js "lang="en-US"> Dwaine Vance, Randox, on Molecular Diagnostics
Thursday, June 08, 2023

Breaking News

New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease MedTech Innovator Asia Pacific Names 24 Startups to Annual Accelerator XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics Abivax Appoints Ida Hatoum as Chief People Officer Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors BioCentriq® and Kytopen® Expand Partnership to Expedite Impact of Transformative Gene-Editing Technology on Cell Therapy Manufacturing FluoGuide Announces Positive Topline Results from Phase IIa Trial of FG001 in Lung Cancer

May 15 2023

Dwaine Vance, Randox, on Molecular Diagnostics

At ECCMID, we caught up with Dwaine Vance from Randox, who discusses his company’s contribution to the field of diagnostics and healthcare. Randox is a leading provider of innovative diagnostic solutions for various medical applications.

Vance begins by highlighting Randox’s commitment to improving patient outcomes through advanced diagnostic technologies. He mentions the company’s extensive range of diagnostic products, including tests for infectious diseases.

He goes on to discuss Randox’s dedication to research and development, emphasizing the company’s investment in cutting-edge technologies and collaborations with renowned institutions. Vance explains that Randox’s focus is on developing accurate and reliable diagnostic tests that can aid in early disease detection, personalized treatment, and improved patient care.

  1. New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes

    News

     Read more
  2. Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Clinical Trials

     Read more
  3. MedTech Innovator Asia Pacific Names 24 Startups to Annual Accelerator

    News

     Read more
  4. XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer

    Appointments

     Read more
  5. Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics

    Gene Therapy

     Read more
More On